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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 4 4 9 – 4 5 2452Second, there are additional statistical challenges to these
tests. DerSimonian and Laird’s [8] Q statistic is specific to random
effects models, while Cochran’s Q statistic [7] is not presented in
the context of covariates: their original derivation is only for
models that do not control for confounding. This is presumably
because the authors are well aware that one cannot directly
compare magnitudes of odds ratios from separate analyses, a
point only recently highlighted in the applied literature [11–13]. In
addition, because of differences in the weighting of trials when
calculating Cochran’s Q for different summary statistics, these
comparisons may not be particularly meaningful and may be
misleading [10].
Third, in practice estimating a model with a rich specification
of covariates can provide a good approximation to other models.
We showed this in another article in which multivariate logistic
regression could recover the adjusted risk ratio even when the
data generating process is an odds ratio [14]. DerSimonian and
Laird [8] also argue that although choosing the wrong measure
could imply heterogeneity in treatment effects, in practice this
would not tend to happen unless the rate for the control group
varied widely or was close to either zero or one.
Fourth, our preferred approach to choosing a measure is to
begin with the policy or research question. Even if this approach
requires tolerating reduced precision because of heterogeneity,
we hold with Tukey [15], ‘‘Far better an approximate answer to
the right question, which is often vague, than an exact answer to
the wrong question, which can always be made precise.’’ We
consider the statistics to serve the substance and not vice versa.
We thank Valkenhoef and Ades for their careful read of our
article, and for drawing attention to important issues about
conducting meta-analyses. Their letter is a great reminder that
assumptions matter, that some statistical models are theoreti-
cally incompatible with seemingly similar models, and that
getting the right statistical model is extremely important. We
hope that this exchange will generate better understanding of the
strengths and weaknesses of different approaches to indirect
comparison meta-analyses.Edward C. Norton, PhD
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